Literature DB >> 20512057

Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life.

Sushrut Jangi1, J Thomas Lamont.   

Abstract

Approximately 60% to 70% of healthy newborns and infants are colonized by the enteric pathogen Clostridium difficile. For reasons that remain obscure, these colonized infants show no ill effects from the potent exotoxins released by this anaerobe, in contrast to older children and adults who are susceptible to severe diarrhea and colitis. The organism is acquired in infancy, as in adults, from environmental contamination in the nursery or home environment. Between 12 and 24 months C difficile is evicted as a commensal, presumably by the gradual development of the adult colonic microflora. The carrier state is well tolerated by infants, and the immunoglobulin G antitoxin response that develops during the carrier state appears to provide durable protection against subsequent C difficile disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20512057     DOI: 10.1097/MPG.0b013e3181d29767

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  89 in total

Review 1.  Diagnosis of Clostridium difficile Infections in Children.

Authors:  Stella Antonara; Amy L Leber
Journal:  J Clin Microbiol       Date:  2016-02-24       Impact factor: 5.948

2.  Toxin-positive Clostridium difficile latently infect mouse colonies and protect against highly pathogenic C. difficile.

Authors:  Lucie Etienne-Mesmin; Benoit Chassaing; Oluwaseyi Adekunle; Lisa M Mattei; Frederic D Bushman; Andrew T Gewirtz
Journal:  Gut       Date:  2017-02-20       Impact factor: 23.059

3.  Toxin-producing Clostridium difficile strains as long-term gut colonizers in healthy infants.

Authors:  Ingegerd Adlerberth; Haihui Huang; Erika Lindberg; Nils Åberg; Bill Hesselmar; Robert Saalman; Carl Erik Nord; Agnes E Wold; Andrej Weintraub
Journal:  J Clin Microbiol       Date:  2013-10-30       Impact factor: 5.948

4.  Real-time cellular analysis coupled with a specimen enrichment accurately detects and quantifies Clostridium difficile toxins in stool.

Authors:  Bin Huang; Dazhi Jin; Jing Zhang; Janet Y Sun; Xiaobo Wang; Jeffrey Stiles; Xiao Xu; Mini Kamboj; N Esther Babady; Yi-Wei Tang
Journal:  J Clin Microbiol       Date:  2014-01-22       Impact factor: 5.948

5.  Treatment of recurrent Clostridium difficile infection using fecal microbiota transplantation in patients with inflammatory bowel disease.

Authors:  Krista M Newman; Kevin M Rank; Byron P Vaughn; Alexander Khoruts
Journal:  Gut Microbes       Date:  2017-01-19

6.  Use of Acid Suppression Medication is Associated With Risk for C. difficile Infection in Infants and Children: A Population-based Study.

Authors:  Daniel E Freedberg; Esi S Lamousé-Smith; Jenifer R Lightdale; Zhezhen Jin; Yu-Xiao Yang; Julian A Abrams
Journal:  Clin Infect Dis       Date:  2015-06-09       Impact factor: 9.079

Review 7.  Intestinal colonization resistance.

Authors:  Trevor D Lawley; Alan W Walker
Journal:  Immunology       Date:  2013-01       Impact factor: 7.397

8.  Environmental Contamination in Households of Patients with Recurrent Clostridium difficile Infection.

Authors:  Megan K Shaughnessy; Aleh Bobr; Michael A Kuskowski; Brian D Johnston; Michael J Sadowsky; Alexander Khoruts; James R Johnson
Journal:  Appl Environ Microbiol       Date:  2016-04-18       Impact factor: 4.792

9.  Intestinal inflammatory biomarkers and outcome in pediatric Clostridium difficile infections.

Authors:  Rana E El Feghaly; Jennifer L Stauber; Phillip I Tarr; David B Haslam
Journal:  J Pediatr       Date:  2013-09-04       Impact factor: 4.406

10.  Longitudinal Investigation of Carriage Rates, Counts, and Genotypes of Toxigenic Clostridium difficile in Early Infancy.

Authors:  Hiroyuki Kubota; Hiroshi Makino; Agata Gawad; Akira Kushiro; Eiji Ishikawa; Takafumi Sakai; Takuya Akiyama; Kazunori Matsuda; Rocio Martin; Jan Knol; Kenji Oishi
Journal:  Appl Environ Microbiol       Date:  2016-09-16       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.